0001562180-19-003677.txt : 20190628 0001562180-19-003677.hdr.sgml : 20190628 20190628170428 ACCESSION NUMBER: 0001562180-19-003677 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190627 FILED AS OF DATE: 20190628 DATE AS OF CHANGE: 20190628 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ross Leonard S CENTRAL INDEX KEY: 0001458753 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 19930261 MAIL ADDRESS: STREET 1: C/O PSIVIDA CORP STREET 2: 400 PLEASANT STREET CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2019-06-27 false 0001314102 EyePoint Pharmaceuticals, Inc. EYPT 0001458753 Ross Leonard S C/O EYEPOINT PHARMACEUTICALS, INC. 480 PLEASANT STREET WATERTOWN MA 02472 false true false false See Remarks Common Stock 2019-06-27 4 M false 6667.00 0.00 A 92005.00 D Common Stock 2019-06-27 4 F false 1961.00 1.65 D 90044.00 D Restricted Stock Units 0.00 2019-06-27 4 M false 6667.00 0.00 D Common Stock 6667.00 6667.00 D Restricted stock units convert into common stock on a one-for-one basis. No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units On June 27, 2017, the reporting person was granted 20,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. VP Finance and Chief Accounting Officer /s/ John Mercer, Attorney-in-Fact 2019-06-28